Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 5Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Hyperuricemia 1Congenital Abnormalities 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Terminated × rasburicase × Clear all
NCT01564277 2018-01-09

Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies

Roswell Park Cancer Institute

Phase 2 Terminated
24 enrolled 13 charts
LymphoidOther hematologic neoplasm

Congenital Abnormalities, Blast Crisis, Burkitt Lymphoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00664144 2012-03-07

GRAAL2

Sanofi

Phase 2 Terminated
33 enrolled

Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡